



Company Number: 369143

Gladstone Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Gladstone Pharmacy Limited

CONTENTS

| | Page |
|---------------------------------------|-------------|
| Director and Other Information | 3 |
| Director's Responsibilities Statement | 4 |
| Balance Sheet | 5 |
| Notes to the Financial Statements | 6 - 8 |

Gladstone Pharmacy Limited
DIRECTOR AND OTHER INFORMATION

| | |
|---|---|
| Director | Suzanne O'Gorman |
| Company Secretary | Brian O'Gorman |
| Company Number | 369143 |
| Registered Office and Business Address | 52 Gladstone Street Clonmel Co. Tipperary Ireland |
| Accountants | O'Gorman Brannigan Purtill & Co. Unlimited Co. Chartered Accountants Anglesea House, Anglesea Street, Clonmel, Co. Tipperary E91 P2C8 |

Gladstone Pharmacy Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The director made the following statement in respect of the unaudited financial statements:

"General responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Director's declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet and the related notes:

The director approves these financial statements and confirms that they is responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The director confirms that they has made available to O'Gorman Brannigan Purtill & Co. Unlimited Co., (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The director confirms that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 April 2025."

Signed on behalf of the board

Suzanne O'Gorman
Director

30 January 2026

Gladstone Pharmacy Limited

BALANCE SHEET

as at 30 April 2025

| | Notes | 2025 € | 2024 € |
|---|-------|------------------|------------------|
| Fixed Assets | | | |
| Tangible assets | 5 | <u>128,928</u> | <u>152,513</u> |
| Current Assets | | | |
| Stocks | 6 | 138,423 | 142,640 |
| Debtors | 7 | 198,968 | 183,964 |
| Cash and cash equivalents | | <u>910,526</u> | <u>760,335</u> |
| | | <u>1,247,917</u> | <u>1,086,939</u> |
| Creditors: amounts falling due within one year | 8 | <u>(55,250)</u> | <u>(48,713)</u> |
| Net Current Assets | | <u>1,192,667</u> | <u>1,038,226</u> |
| Total Assets less Current Liabilities | | <u>1,321,595</u> | <u>1,190,739</u> |
| Capital and Reserves | | | |
| Called up share capital presented as equity | | 48 | 48 |
| Retained earnings | 9 | <u>1,321,547</u> | <u>1,190,691</u> |
| Shareholders' Funds | | <u>1,321,595</u> | <u>1,190,739</u> |

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Gladstone Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 30 January 2026 and signed on its behalf by:

Suzanne O'Gorman
Director

Gladstone Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Gladstone Pharmacy Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 369143. The registered office of the company is 52 Gladstone Street, Clonmel, Co.Tipperary, Ireland which is also the principal place of business of the company. The principal activity of the company is running a pharmacy dispensing chemist and retailer of pharmaceutical and beauty products. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

| | | |
|----------------------------------|---|-------------------------|
| Fixtures, fittings and equipment | - | 10% / 20% Straight line |
|----------------------------------|---|-------------------------|

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Gladstone Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

| | | |
|---|-------------------|-------------------|
| 3. Operating profit | 2025 | 2024 |
| | € | € |
| Operating profit is stated after charging/(crediting): | | |
| Depreciation of tangible assets | 25,854 | 25,400 |
| (Profit)/loss on disposal of tangible assets | - | 1,680 |
| Government grants received | (1,444) | - |
| | <u> </u> | <u> </u> |

4. Employees

The average monthly number of employees, including director, during the financial year was 11 ,(2024 - 10).

5. Tangible assets

| | Fixtures, fittings and equipment | Total |
|-------------------------------|---|-------------------|
| | € | € |
| Cost | | |
| At 1 May 2024 | 254,004 | 254,004 |
| Additions | 2,269 | 2,269 |
| | <u> </u> | <u> </u> |
| At 30 April 2025 | 256,273 | 256,273 |
| | <u> </u> | <u> </u> |
| Depreciation | | |
| At 1 May 2024 | 101,491 | 101,491 |
| Charge for the financial year | 25,854 | 25,854 |
| | <u> </u> | <u> </u> |
| At 30 April 2025 | 127,345 | 127,345 |
| | <u> </u> | <u> </u> |
| Net book value | | |
| At 30 April 2025 | 128,928 | 128,928 |
| | <u> </u> | <u> </u> |
| At 30 April 2024 | 152,513 | 152,513 |
| | <u> </u> | <u> </u> |

| | | |
|-------------------------------------|-------------------|-------------------|
| 6. Stocks | 2025 | 2024 |
| | € | € |
| Finished goods and goods for resale | 138,423 | 142,640 |
| | <u> </u> | <u> </u> |

The replacement cost of stock did not differ significantly from the figures shown.

Gladstone Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

| | | |
|--|------------------|------------------|
| 7. Debtors | 2025 | 2024 |
| | € | € |
| Other debtors | 117,207 | 104,466 |
| Taxation | 81,761 | 79,498 |
| | <u>198,968</u> | <u>183,964</u> |
| 8. Creditors | 2025 | 2024 |
| Amounts falling due within one year | € | € |
| Trade creditors | 7,408 | 13,782 |
| Taxation | 30,468 | 17,557 |
| Director's current account (Note 11) | 13,374 | 12,634 |
| Other creditors | - | 740 |
| Accruals | 4,000 | 4,000 |
| | <u>55,250</u> | <u>48,713</u> |
| 9. Income Statement | | |
| | 2025 | 2024 |
| | € | € |
| At 1 May 2024 as previously stated | 1,190,691 | 1,074,041 |
| Prior financial year error correction | - | (97,608) |
| At 1 May 2024 | <u>1,190,691</u> | <u>976,433</u> |
| Profit for the financial year | 130,856 | 214,258 |
| At 30 April 2025 | <u>1,321,547</u> | <u>1,190,691</u> |
| 10. Capital commitments | | |
| The company had no material capital commitments at the financial year-ended 30 April 2025. | | |
| 11. Director's remuneration and transactions | 2025 | 2024 |
| | € | € |
| Remuneration | 109,200 | 109,200 |
| Pension contributions | 56,297 | 46,183 |
| | <u>165,497</u> | <u>155,383</u> |
| The following amounts are repayable to the director: | | |
| | 2025 | 2024 |
| | € | € |
| Suzanne O'Gorman | <u>13,374</u> | <u>12,634</u> |
| 12. Post-Balance Sheet Events | | |
| There have been no significant events affecting the company since the financial year-end. | | |
| 13. Approval of financial statements | | |
| The financial statements were approved and authorised for issue by the board on 30 January 2026. | | |

